Literature DB >> 20643121

Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model.

Beatrice Waser1, Renzo Cescato, Maria-Luisa Tamma, Helmut R Maecke, Jean Claude Reubi.   

Abstract

Among clinically relevant somatostatin functions, agonist-induced somatostatin receptor subtype 2 (sst(2)) internalization is a potent mechanism for tumor targeting with sst(2) affine radioligands such as octreotide. Since, as opposed to octreotide, the second generation multi-somatostatin analog SOM230 (pasireotide) exhibits strong functional selectivity, it appeared of interest to evaluate its ability to affect sst(2) internalization in vivo. Rats bearing AR42J tumors endogenously expressing somatostatin sst(2) receptors were injected intravenously with SOM230 or with the [Tyr(3), Thr(8)]-octreotide (TATE) analog; they were euthanized at various time points; tumors and pancreas were analyzed by immunohistochemistry for the cellular localization of somatostatin sst(2) receptors. SOM230-induced sst(2) internalization was also evaluated in vitro by immunofluorescence microscopy in AR42J cells. At difference to the efficient in vivo sst(2) internalization triggered by intravenous [Tyr(3), Thr(8)]-octreotide, intravenous SOM230 did not elicit sst(2) internalization: immunohistochemically stained sst(2) in AR42J tumor cells and pancreatic cells were detectable at the cell surface at 2.5min, 10min, 1h, 6h, or 24h after SOM230 injection while sst(2) were found intracellularly after [Tyr(3), Thr(8)]-octreotide injection. The inability of stimulating sst(2) internalization by SOM230 was confirmed in vitro in AR42J cells by immunofluorescence microscopy. Furthermore, SOM230 was unable to antagonize agonist-induced sst(2) internalization, neither in vivo, nor in vitro. Therefore, SOM230 does not induce sst(2) internalization in vivo or in vitro in AR42J cells and pancreas, at difference to octreotide derivatives with comparable sst(2) binding affinities. These characteristics may point towards different tumor targeting but also to different desensitization properties of clinically applied SOM230. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20643121     DOI: 10.1016/j.ejphar.2010.07.005

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists.

Authors:  Yachu J Kao; Madhumita Ghosh; Agnes Schonbrunn
Journal:  Mol Endocrinol       Date:  2011-04-14

2.  [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study.

Authors:  Aikaterini Tatsi; Theodosia Maina; Renzo Cescato; Beatrice Waser; Eric P Krenning; Marion de Jong; Paul Cordopatis; Jean Claude Reubi; Berthold A Nock
Journal:  EJNMMI Res       Date:  2012-06-09       Impact factor: 3.138

3.  Neodymium-140 DOTA-LM3: Evaluation of an In Vivo Generator for PET with a Non-Internalizing Vector.

Authors:  Gregory W Severin; Lotte K Kristensen; Carsten H Nielsen; Jesper Fonslet; Andreas I Jensen; Anders F Frellsen; K M Jensen; Dennis R Elema; Helmut Maecke; Andreas Kjær; Karl Johnston; Ulli Köster
Journal:  Front Med (Lausanne)       Date:  2017-07-12

4.  Peptide receptor targeting in cancer: the somatostatin paradigm.

Authors:  Federica Barbieri; Adriana Bajetto; Alessandra Pattarozzi; Monica Gatti; Roberto Würth; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Tullio Florio
Journal:  Int J Pept       Date:  2013-02-07

Review 5.  Pasireotide in the Personalized Treatment of Acromegaly.

Authors:  Manel Puig-Domingo; Ignacio Bernabéu; Antonio Picó; Betina Biagetti; Joan Gil; Cristina Alvarez-Escolá; Mireia Jordà; Montserrat Marques-Pamies; Berta Soldevila; María-Angeles Gálvez; Rosa Cámara; Javier Aller; Cristina Lamas; Mónica Marazuela
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-16       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.